Animal models of depression

Last updated

Animal models of depression are research tools used to investigate depression and action of antidepressants. They are used as a simulation to investigate the symptomatology and pathophysiology of depressive illness and to screen novel antidepressants. These models provide insights into molecular, genetic, and epigenetic factors associated with depression. Criteria for valid animal models include face, construct, and predictive validity. Endophenotypes, such as anhedonia, behavioral despair, changes in appetite, neuroanatomical alterations, neuroendocrine disturbances, alterations in sleep architecture, and anxiety-related behaviors, are evaluated in these models. Antidepressant screening tests are employed to assess the effects of genetic, pharmacological, or environmental manipulations. Stress models including learned helplessness, chronic mild stress, and social defeat stress simulate the impact of stressors on depression. Early life stress models, psychostimulant withdrawal models, olfactory bulbectomy, and genetically engineered mice contribute to a comprehensive understanding of depression's etiology and potential therapeutic interventions.

Contents

Introduction

Depression

Major depressive disorder is commonly called "clinical depression" or "depression." It is a common, long-lasting and diverse psychiatric syndrome that significantly affects a person's thoughts, behavior, feelings and sense of well-being. According to the DSM-5, someone diagnosed with depression should be showing at least five symptoms and they should last two weeks. [1] Depression can include a variety of different symptoms and does not always look the same for everyone. Some of these symptoms may include sadness, anxiousness, emptiness, hopelessness, worry, helplessness, worthlessness, guilt, irritableness, hurt, or restlessness. People experiencing depression may also lose interest in activities that once were pleasurable, experience loss of appetite, overeat, have problems concentrating, remembering details, making decisions, and may contemplate or attempt suicide. Insomnia, excessive sleeping, fatigue, loss of energy, aches, pains, or digestive problems that are resistant to treatment may also be present. [2]

Modeling depression in animals

It is difficult to develop an animal model that perfectly reproduces the symptoms of depression in patients. It is generic that 3 standards may be used to evaluate the reliability of an animal version of depression: the phenomenological or morphological appearances (face validity), a comparable etiology (assemble validity), and healing similarities (predictive validity). Many animals lack self-consciousness, self-reflection, and consideration; moreover, hallmarks of the disorder such as depressed mood, low self-esteem or suicidality are hardly accessible in non-humans. However, depression, as other mental disorders, consists of endophenotypes [3] that can be reproduced independently and evaluated in animals. An ideal animal model offers an opportunity to understand molecular, genetic, and epigenetic factors that may lead to depression. By using animal models, the underlying molecular alterations and the causal relationship between genetic, or environmental, alterations and depression can be examined. This would afford a better insight into pathology of depression because animal models are indispensable for identifying novel therapies for depression. [4]

Endophenotypes in animal model of depression

The following endophenotypes have been described: [3]

Criteria for valid animal models of depression

An appropriate animal model of human depression should fulfill the following criteria as much as possible: strong phenomenological similarities and similar pathophysiology (face validity), comparable etiology (construct validity), and common treatment (predictive validity). [6] [7] [8] Depression is a heterogeneous disorder and its many symptoms are hard to produce in laboratory animals. When studying depression used in animals originally, symptoms equivalent to odd social behavior and emotion were used to determine if the animal had depression. [9] The question therefore remains whether we can know if the animal is "depressed". They are unable to have the emotions that are associated specifically with humans, like sadness. [10] Few models of depression fully fit these validating criteria, and most models currently used rely on either actions of known antidepressants or responses to stress. It is not necessary for an "ideal" animal model of depression to exhibit all the abnormalities of depression-relevant behaviors, just as not all patients manifest every possible symptom of depression.

Animal Model Tests

Despair-based

Forced-swimming test Forced-swimming test.jpg
Forced-swimming test
The advantages of FST are that it is low-cost and a fast, reliable tool. It is also easy to handle and has proven its reliability across laboratories for testing potential antidepressant activities with a strong predictive validity and it allows rapid screening of large numbers of drugs. The major disadvantages of FST are that it has poor face and construct validities. The test is sensitive to acute treatment only, and its validity for non-monoamine antidepressants is uncertain
Tail suspension test Mice tail suspension test (TST).jpg
Tail suspension test
A major advantage of the TST is that it is simple and inexpensive. A major disadvantage of the TST is that it is restricted to mice. Like FST, TST is sensitive to acute treatment only, and its validity for non-monoamine antidepressants is uncertain.

Reward-based

Open field Circular Open Field.jpg
Open field

Anxiety-based

Elevated plus maze PlusMaze.jpg
Elevated plus maze
Dark/light box Dark-Light box.jpg
Dark/light box

Stress models

Certain types of human depression are precipitated by stressful life events, and vulnerable individuals experiencing these stressors. Consequently, the majority of animal models of depression are based on the exposure to various types of acute or chronic stressors.

Adult stress models

An advantage of LH is that the cognitive and other behavioral outcomes seem to be correlated, thus helping to understand the depressive symptomatology in humans. This model can also be generally used to measure the escape performance of mice with different mutations in which target genes of depression may affect the vulnerability to develop a depressive-like state. These excellent face and predictive validities make LH an interesting model to explore the pathophysiology of depression. The biggest disadvantage of LH is it requires very strong stressors to induce the behavioral phenotypes which does raise ethical problems. Also, most of the symptoms do not persist long enough following cessation of the uncontrollable shock.
The advantages of this model are its good predictive validity (behavioral changes are reversed by chronic treatment with a wide variety of antidepressants), face validity (almost all demonstrable symptoms of depression have been reproduced), and construct validity (CMS causes a generalized decrease in responsiveness to rewards). However, there is a common practical difficulty in carrying out CMS experiments, which are labor intensive, demanding of space, and of long duration. The procedure can be difficult to be established and data can be hardly replicated.
Like CMS, SDS has good predictive validity (behavioral changes are reversed by chronic treatment with a wide variety of antidepressants), face validity (many symptoms of depression have been reproduced), and construct validity (causing a generalized decrease in responsiveness to rewards). SDS gives another validity that only chronic, but not acute, antidepressant administration can reverse the social aversion. One disadvantage of SDS model is the long duration. To apply an SDS model for studying human depression, the period of it should last at least 20 days or only anxiety symptoms could be induced. Only male rodents can be used for this model, since female rodents do not fight each other in a resident–intruder confrontation.

Early life stress models

Early adverse experiences such as traumatic life events in childhood result in an increased sensitivity to the effects of stress later in life and influence the vulnerability to depression. [31] Suitable animal models could provide a basis for understanding potential mechanisms of environmental and developmental factors of individual differences in stress reactivity and vulnerability to disorders. Models of early life stress involve prenatal stress, early postnatal handling and maternal separation. All these treatments have been demonstrated to produce significant effects that last until adulthood.

Other models

Benefits of Animal Models

A benefit to this model of research is the production of antidepressants. While antidepressants are helpful, the effects of current antidepressant drugs are often significantly delayed, with improvements beginning around 3–6 weeks after treatment is started. Antidepressant screening tests provide only an end-point behavioral or physiological measure designed to assess the effect of the genetic, pharmacological, or environmental manipulation. This is unlike models which can be defined as an organism or a particular state of an organism that reproduces aspects of human pathology. Despite the clinical success of many antidepressant drugs, such as tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs), and serotonin reuptake inhibitors (SRIs), many individuals' symptoms are not adequately alleviated by medication alone, and other methods of treatment may be recommended. [39] [40] Antidepressant and depression research is ongoing. There is a lot more knowledge now and people struggling have access to the tools they need when seeking help. Animal research has been a successful way for experts to gain this knowledge and it continues to have positive impacts in the medical field and beyond.

See also

Related Research Articles

<span class="mw-page-title-main">Mood disorder</span> Mental disorder affecting the mood of an individual, over a long period of time

A mood disorder, also known as an affective disorder, is any of a group of conditions of mental and behavioral disorder where the main underlying characteristic is a disturbance in the person's mood. The classification is in the Diagnostic and Statistical Manual of Mental Disorders (DSM) and International Classification of Diseases (ICD).

<span class="mw-page-title-main">Anhedonia</span> Inability to feel pleasure

Anhedonia is a diverse array of deficits in hedonic function, including reduced motivation or ability to experience pleasure. While earlier definitions emphasized the inability to experience pleasure, anhedonia is currently used by researchers to refer to reduced motivation, reduced anticipatory pleasure (wanting), reduced consummatory pleasure (liking), and deficits in reinforcement learning. In the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), anhedonia is a component of depressive disorders, substance-related disorders, psychotic disorders, and personality disorders, where it is defined by either a reduced ability to experience pleasure, or a diminished interest in engaging in previously pleasurable activities. While the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) does not explicitly mention anhedonia, the depressive symptom analogous to anhedonia as described in the DSM-5 is a loss of interest or pleasure.

Dysthymia, also known as persistent depressive disorder (PDD), is a mental and behavioral disorder, specifically a disorder primarily of mood, consisting of similar cognitive and physical problems as major depressive disorder, but with longer-lasting symptoms. The concept was used by Robert Spitzer as a replacement for the term "depressive personality" in the late 1970s.

Atypical depression is defined in the DSM-IV as depression that shares many of the typical symptoms of major depressive disorder or dysthymia but is characterized by improved mood in response to positive events. In contrast to those with atypical depression, people with melancholic depression generally do not experience an improved mood in response to normally pleasurable events. Atypical depression also often features significant weight gain or an increased appetite, hypersomnia, a heavy sensation in the limbs, and interpersonal rejection sensitivity that results in significant social or occupational impairment.

<span class="mw-page-title-main">Emotional detachment</span> Inability and/or disinterest in emotionally connecting to others

In psychology, emotional detachment, also known as emotional blunting, is a condition or state in which a person lacks emotional connectivity to others, whether due to an unwanted circumstance or as a positive means to cope with anxiety. Such a coping strategy, also known as emotion-focused coping, is used when avoiding certain situations that might trigger anxiety. It refers to the evasion of emotional connections. Emotional detachment may be a temporary reaction to a stressful situation, or a chronic condition such as depersonalization-derealization disorder. It may also be caused by certain antidepressants. Emotional blunting, also known as reduced affect display, is one of the negative symptoms of schizophrenia.

An anxiogenic or panicogenic substance is one that causes anxiety. This effect is in contrast to anxiolytic agents, which inhibits anxiety. Together these categories of psychoactive compounds may be referred to as anxiotropic compounds.

In biology and behavioural psychology, social defeat refers to the physiological and behavioral effects on the losing party in a confrontation among animals of the same species, or in any kind of hostile dispute among humans. Social defeat can potentially greatly affect an individual's control over resources, access to mates, and social position, and the term is used in both dyadic (one-on-one) and group-individual contexts.

Psychological dependence is a cognitive disorder and a form of dependence that is characterized by emotional–motivational withdrawal symptoms upon cessation of prolonged drug use or certain repetitive behaviors. Consistent and frequent exposure to particular substances or behaviors is responsible for inducing psychological dependence, requiring ongoing engagement to prevent the onset of an unpleasant withdrawal syndrome driven by negative reinforcement. Neuronal counter-adaptation is believed to contribute to the generation of withdrawal symptoms through changes in neurotransmitter activity or altered receptor expression. Environmental enrichment and physical activity have been shown to attenuate withdrawal symptoms.

<span class="mw-page-title-main">Elevated plus maze</span> Scientific test for laboratory mice

The elevated plus maze (EPM) is a test measuring anxiety in laboratory animals that usually uses rodents as a screening test for putative anxiolytic or anxiogenic compounds and as a general research tool in neurobiological anxiety research such as PTSD and TBI. The model is based on the test animal's aversion to open spaces and tendency to be thigmotaxic. In the EPM, this anxiety is expressed by the animal spending more time in the enclosed arms. The validity of the model has been criticized as non-classical clinical anxiolytics produce mixed results in the EPM test. Despite this, the model is still commonly used for screening putative anxiolytics and for general research into the brain mechanisms of anxiety.

Scientific studies have found that different brain areas show altered activity in humans with major depressive disorder (MDD), and this has encouraged advocates of various theories that seek to identify a biochemical origin of the disease, as opposed to theories that emphasize psychological or situational causes. Factors spanning these causative groups include nutritional deficiencies in magnesium, vitamin D, and tryptophan with situational origin but biological impact. Several theories concerning the biologically based cause of depression have been suggested over the years, including theories revolving around monoamine neurotransmitters, neuroplasticity, neurogenesis, inflammation and the circadian rhythm. Physical illnesses, including hypothyroidism and mitochondrial disease, can also trigger depressive symptoms.

<span class="mw-page-title-main">Tail suspension test</span> Animal behavioural test

The tail suspension test (TST) is an experimental method used in scientific research to measure stress in rodents. It is based on the observation that if a mouse is subjected to short term inescapable stress then the mouse will become immobile. It is used to measure the effectiveness of antidepressant-like agents but there is significant controversy over its interpretation and usefulness.

<span class="mw-page-title-main">ALTO-100</span> BDNF-modulating drug for depression and PTSD

ALTO-100, previously known as NSI-189, is a drug described as a hippocampal neurogenesis stimulant and indirect brain-derived neurotrophic factor (BDNF) modulator which is under development for the treatment of major depressive disorder (MDD), bipolar depression, and post-traumatic stress disorder (PTSD). There has also been interest in ALTO-100 for possible treatment of cognitive impairment and neurodegeneration. It is taken by mouth.

The pharmacology of antidepressants is not entirely clear. The earliest and probably most widely accepted scientific theory of antidepressant action is the monoamine hypothesis, which states that depression is due to an imbalance of the monoamine neurotransmitters. It was originally proposed based on the observation that certain hydrazine anti-tuberculosis agents produce antidepressant effects, which was later linked to their inhibitory effects on monoamine oxidase, the enzyme that catalyses the breakdown of the monoamine neurotransmitters. All currently marketed antidepressants have the monoamine hypothesis as their theoretical basis, with the possible exception of agomelatine which acts on a dual melatonergic-serotonergic pathway. Despite the success of the monoamine hypothesis it has a number of limitations: for one, all monoaminergic antidepressants have a delayed onset of action of at least a week; and secondly, there are a sizeable portion (>40%) of depressed patients that do not adequately respond to monoaminergic antidepressants. Further evidence to the contrary of the monoamine hypothesis are the recent findings that a single intravenous infusion with ketamine, an antagonist of the NMDA receptor — a type of glutamate receptor — produces rapid, robust and sustained antidepressant effects. Monoamine precursor depletion also fails to alter mood. To overcome these flaws with the monoamine hypothesis a number of alternative hypotheses have been proposed, including the glutamate, neurogenic, epigenetic, cortisol hypersecretion and inflammatory hypotheses. Another hypothesis that has been proposed which would explain the delay is the hypothesis that monoamines don't directly influence mood, but influence emotional perception biases.

<span class="mw-page-title-main">Buprenorphine/samidorphan</span> Combination drug formulation

Buprenorphine/samidorphan is a combination formulation of buprenorphine and samidorphan which is under development as an add on to antidepressants in treatment-resistant depression (TRD).

Epigenetics of depression is the study of how epigenetics contribute to depression.

<span class="mw-page-title-main">Marble burying</span> Animal model used in scientific research

Marble burying is an animal model used in scientific research to depict anxiety or obsessive–compulsive disorder (OCD) behavior. It is based on the observation that rats and mice will bury either harmful or harmless objects in their bedding. While widely used there is significant controversy over the interpretation of its results.

Immuno-psychiatry, according to Pariante, is a discipline that studies the connection between the brain and the immune system. It differs from psychoneuroimmunology by postulating that behaviors and emotions are governed by peripheral immune mechanisms. Depression, for instance, is seen as malfunctioning of the immune system.

Epigenetics of anxiety and stress–related disorders is the field studying the relationship between epigenetic modifications of genes and anxiety and stress-related disorders, including mental health disorders such as generalized anxiety disorder (GAD), post-traumatic stress disorder, obsessive-compulsive disorder (OCD), and more. These changes can lead to transgenerational stress inheritance.

Angela J. Grippo is an American neuroscientist and health psychologist known for her research on stress, mood disorders, and cardiovascular disease. She is an associate professor of psychology at Northern Illinois University.

<span class="mw-page-title-main">Neurogenesis hypothesis of depression</span> Theory of depression

Adult neurogenesis is the process by which functional, mature neurons are produced from neural stem cells (NSCs) in the adult brain. In most mammals, including humans, it only occurs in the subgranular zone of the hippocampus, and in the olfactory bulb. The neurogenesis hypothesis of depression proposes that major depressive disorder is caused, at least partly, by impaired neurogenesis in the subgranular zone of the hippocampus.

References

  1. Tolentino, Julio C.; Schmidt, Sergio L. (2018-10-02). "DSM-5 Criteria and Depression Severity: Implications for Clinical Practice". Frontiers in Psychiatry. 9: 450. doi: 10.3389/fpsyt.2018.00450 . ISSN   1664-0640. PMC   6176119 . PMID   30333763.
  2. "Depression Basics". National Institute of Mental Health. Archived from the original on 2013-06-11. Retrieved 2013-05-07.
  3. 1 2 Hasler, Gregor; Drevets, Wayne C; Manji, Husseini K; Charney, Dennis S (2004-06-23). "Discovering Endophenotypes for Major Depression". Neuropsychopharmacology. 29 (10): 1765–1781. doi: 10.1038/sj.npp.1300506 . ISSN   0893-133X. PMID   15213704.
  4. Hao, Yuanzhen, Huixiang Ge, Mengyun Sun, and Yun Gao. 2019. "Selecting an Appropriate Animal Model of Depression" International Journal of Molecular Sciences 20, no. 19: 4827. https://doi.org/10.3390/ijms20194827
  5. Chevalier, Grégoire; Siopi, Eleni; Guenin-Macé, Laure; Pascal, Maud; Laval, Thomas; Rifflet, Aline; Boneca, Ivo Gomperts; Demangel, Caroline; Colsch, Benoit; Pruvost, Alain; Chu-Van, Emeline; Messager, Aurélie; Leulier, François; Lepousez, Gabriel; Eberl, Gérard (2020-12-11). "Effect of gut microbiota on depressive-like behaviors in mice is mediated by the endocannabinoid system". Nature Communications. 11 (1): 6363. Bibcode:2020NatCo..11.6363C. doi:10.1038/s41467-020-19931-2. ISSN   2041-1723.
  6. Willner, P.; Mitchell, P. J. (May 2002). "The validity of animal models of predisposition to depression". Behavioural Pharmacology. 13 (3): 169–188. doi:10.1097/00008877-200205000-00001. ISSN   0955-8810. PMID   12122308.
  7. Anisman, Hymie; Matheson, Kim (January 2005). "Stress, depression, and anhedonia: Caveats concerning animal models". Neuroscience & Biobehavioral Reviews. 29 (4–5): 525–546. doi:10.1016/j.neubiorev.2005.03.007. ISSN   0149-7634. PMID   15925696. S2CID   5904832.
  8. Vollmayr, Barbara; Mahlstedt, Magdalena M.; Henn, Fritz A. (2007-04-01). "Neurogenesis and depression: what animal models tell us about the link". European Archives of Psychiatry and Clinical Neuroscience. 257 (5): 300–303. doi:10.1007/s00406-007-0734-2. ISSN   0940-1334. PMID   17401725. S2CID   16130112.
  9. Becker, Maria; Pinhasov, Albert; Ornoy, Asher (January 14, 2021). "Animal Models of Depression: What Can They Teach Us about the Human Disease?". Diagnostics. 11 (1): 123. doi: 10.3390/diagnostics11010123 . ISSN   2075-4418. PMC   7830961 . PMID   33466814.
  10. Abelaira, Helena M.; Réus, Gislaine Z.; Quevedo, João (2013). "Animal models as tools to study the pathophysiology of depression". Brazilian Journal of Psychiatry. 35: S112–S120. doi:10.1590/1516-4446-2013-1098. ISSN   1516-4446.
  11. Petit-Demouliere, Benoit; Chenu, Franck; Bourin, Michel (2005). "Forced swimming test in mice: a review of antidepressant activity". Psychopharmacology. 177 (3): 245–255. doi:10.1007/s00213-004-2048-7. PMID   15609067. S2CID   1222576.
  12. Cryan, John F.; Mombereau, Cedric; Vassout, Annick (January 2005). "The tail suspension test as a model for assessing antidepressant activity: Review of pharmacological and genetic studies in mice". Neuroscience & Biobehavioral Reviews. 29 (4–5): 571–625. doi:10.1016/j.neubiorev.2005.03.009. ISSN   0149-7634. PMID   15890404. S2CID   2758433.
  13. 1 2 Nielsen, Christina Kurre; Arnt, Jorn; Sánchez, Connie (January 2000). "Intracranial self-stimulation and sucrose intake differ as hedonic measures following chronic mild stress: interstrain and interindividual differences" (PDF). Behavioural Brain Research. 107 (1–2): 21–33. doi:10.1016/S0166-4328(99)00110-2. ISSN   0166-4328. PMID   10628727. S2CID   4001711.[ dead link ]
  14. Verharen, Jeroen P.H.; de Jong, Johannes W.; Zhu, Yichen; Lammel, Stephan (April 2023). "A computational analysis of mouse behavior in the sucrose preference test" (PDF). Nature Communications. 14 (1): 2419. Bibcode:2023NatCo..14.2419V. doi:10.1038/s41467-023-38028-0. ISSN   2041-1723. PMC   10140068 . PMID   37105954.[ dead link ]
  15. Dulawa, Stephanie C.; Hen, Rene (January 2005). "Recent advances in animal models of chronic antidepressant effects: The novelty-induced hypophagia test". Neuroscience & Biobehavioral Reviews. 29 (4–5): 771–783. doi:10.1016/j.neubiorev.2005.03.017. ISSN   0149-7634. PMID   15890403. S2CID   21949826.
  16. 1 2 3 Holmes, A. (May 2001). "Targeted gene mutation approaches to the study of anxiety-like behavior in mice". Neuroscience and Biobehavioral Reviews. 25 (3): 261–273. doi:10.1016/S0149-7634(01)00012-4. ISSN   0149-7634. PMID   11378180. S2CID   7947941.
  17. Drugan, R. C.; Basile, A. S.; Ha, J. H.; Healy, D.; Ferland, R. J. (1997-12-01). "Analysis of the importance of controllable versus uncontrollable stress on subsequent behavioral and physiological functioning". Brain Research. Brain Research Protocols. 2 (1): 69–74. doi: 10.1016/S1385-299X(97)00031-7 . ISSN   1385-299X. PMID   9438074.
  18. Grahn, R. E.; Watkins, L. R.; Maier, S. F. (July 2000). "Impaired escape performance and enhanced conditioned fear in rats following exposure to an uncontrollable stressor are mediated by glutamate and nitric oxide in the dorsal raphe nucleus". Behavioural Brain Research. 112 (1–2): 33–41. doi:10.1016/S0166-4328(00)00161-3. ISSN   0166-4328. PMID   10862933. S2CID   33316951.
  19. Durgam, Robert C. (May 2001). "Rodent Models of Depression: Learned Helplessness Using a Triadic Design in Rats". Current Protocols in Neuroscience. Chapter 8: 8.10B.1–8.10B.12. doi:10.1002/0471142301.ns0810bs14. ISBN   978-0471142300. PMID   18428537. S2CID   7360339.
  20. Chourbaji, S.; Zacher, C.; Sanchis-Segura, C.; Dormann, C.; Vollmayr, B.; Gass, P. (December 2005). "Learned helplessness: Validity and reliability of depressive-like states in mice". Brain Research Protocols. 16 (1–3): 70–78. doi:10.1016/j.brainresprot.2005.09.002. ISSN   1385-299X. PMID   16338640.
  21. Vollmayr, B.; Henn, F. A. (August 2001). "Learned helplessness in the rat: improvements in validity and reliability". Brain Research. Brain Research Protocols. 8 (1): 1–7. doi:10.1016/S1385-299X(01)00067-8. ISSN   1385-299X. PMID   11522522.
  22. Willner, Paul (2005). "Chronic Mild Stress (CMS) Revisited: Consistency and Behavioural-Neurobiological Concordance in the Effects of CMS". Neuropsychobiology. 52 (2): 90–110. doi:10.1159/000087097. ISSN   0302-282X. PMID   16037678. S2CID   22504035.
  23. Willner, P.; Muscat, R.; Papp, M. (1992). "Chronic mild stress-induced anhedonia: a realistic animal model of depression". Neuroscience and Biobehavioral Reviews. 16 (4): 525–534. doi:10.1016/S0149-7634(05)80194-0. ISSN   0149-7634. PMID   1480349. S2CID   9078352.
  24. Monleon, S.; D'Aquila, P.; Parra, A.; Simon, V. M.; Brain, P. F.; Willner, P. (February 1995). "Attenuation of sucrose consumption in mice by chronic mild stress and its restoration by imipramine". Psychopharmacology. 117 (4): 453–457. doi:10.1007/BF02246218. ISSN   0033-3158. PMID   7604147. S2CID   36727320.
  25. Stemmelin, Jeanne; Cohen, Caroline; Yalcin, Ipek; Keane, Peter; Griebel, Guy (January 2010). "Implication of β3-adrenoceptors in the antidepressant-like effects of amibegron using Adrb3 knockout mice in the chronic mild stress". Behavioural Brain Research. 206 (2): 310–312. doi:10.1016/j.bbr.2009.09.003. ISSN   0166-4328. PMID   19744528. S2CID   23269414.
  26. Zhao, Dan; Xu, Xulin; Pan, Linna; Zhu, Wei; Fu, Xiaopei; Guo, Lianjun; Lu, Qing; Wang, Jian (December 2017). "Pharmacologic activation of cholinergic alpha7 nicotinic receptors mitigates depressive-like behavior in a mouse model of chronic stress". Journal of Neuroinflammation. 14 (1): 234. doi: 10.1186/s12974-017-1007-2 . ISSN   1742-2094. PMC   5712092 . PMID   29197398.
  27. Blanchard, R. J.; McKittrick, C. R.; Blanchard, D. C. (June 2001). "Animal models of social stress: effects on behavior and brain neurochemical systems" (PDF). Physiology & Behavior. 73 (3): 261–271. doi:10.1016/S0031-9384(01)00449-8. ISSN   0031-9384. PMID   11438351. S2CID   26571582. Archived from the original (PDF) on 2018-07-28. Retrieved 2018-07-28.
  28. Krishnan, Vaishnav; Han, Ming-Hu; Graham, Danielle L.; Berton, Olivier; Renthal, William; Russo, Scott J.; LaPlant, Quincey; Graham, Ami; Lutter, Michael (October 2007). "Molecular Adaptations Underlying Susceptibility and Resistance to Social Defeat in Brain Reward Regions". Cell. 131 (2): 391–404. doi: 10.1016/j.cell.2007.09.018 . ISSN   0092-8674. PMID   17956738.
  29. Cryan, John F; Slattery, David A (January 2007). "Animal models of mood disorders: recent developments" (PDF). Current Opinion in Psychiatry. 20 (1): 1–7. doi:10.1097/yco.0b013e3280117733. ISSN   0951-7367. PMID   17143074. S2CID   2320195.[ dead link ]
  30. Kudryavtseva, N. N.; Bakshtanovskaya, I. V.; Koryakina, L. A. (February 1991). "Social model of depression in mice of C57BL/6J strain". Pharmacology Biochemistry and Behavior. 38 (2): 315–320. doi:10.1016/0091-3057(91)90284-9. ISSN   0091-3057. PMID   2057501. S2CID   24450372.
  31. McEwen, Bruce S. (2003). "Early life influences on life-long patterns of behavior and health". Mental Retardation and Developmental Disabilities Research Reviews. 9 (3): 149–154. doi:10.1002/mrdd.10074. ISSN   1080-4013. PMID   12953293.
  32. Meaney, Michael J (March 2001). "Maternal Care, Gene Expression, and the Transmission of Individual Differences in Stress Reactivity Across Generations". Annual Review of Neuroscience. 24 (1): 1161–1192. doi:10.1146/annurev.neuro.24.1.1161. ISSN   0147-006X. PMID   11520931.
  33. Song, Cai; Leonard, Brian E. (2005). "The olfactory bulbectomised rat as a model of depression". Neuroscience & Biobehavioral Reviews. 29 (4–5): 627–647. doi:10.1016/j.neubiorev.2005.03.010. ISSN   0149-7634. PMID   15925697. S2CID   42450349.
  34. O'Neil, Michael F.; Moore, Nicholas A. (2003). "Animal models of depression: are there any?". Human Psychopharmacology: Clinical and Experimental. 18 (4): 239–254. doi: 10.1002/hup.496 . ISSN   0885-6222. PMID   12766928. S2CID   21885931.
  35. Schramm, Nicole L.; McDonald, Michael P.; Limbird, Lee E. (2001-07-01). "The α2A-Adrenergic Receptor Plays a Protective Role in Mouse Behavioral Models of Depression and Anxiety". Journal of Neuroscience. 21 (13): 4875–4882. doi: 10.1523/jneurosci.21-13-04875.2001 . PMC   6762349 . PMID   11425914.
  36. Ridder, Stephanie; Chourbaji, Sabine; Hellweg, Rainer; Urani, Alexandre; Zacher, Christiane; Schmid, Wolfgang; Zink, Mathias; Hörtnagl, Heide; Flor, Herta (2005-06-29). "Mice with Genetically Altered Glucocorticoid Receptor Expression Show Altered Sensitivity for Stress-Induced Depressive Reactions". Journal of Neuroscience. 25 (26): 6243–6250. doi: 10.1523/jneurosci.0736-05.2005 . PMC   6725059 . PMID   15987954.
  37. Pliakas, A. M.; Carlson, R. R.; Neve, R. L.; Konradi, C.; Nestler, E. J.; Carlezon, W. A. (2001-09-15). "Altered responsiveness to cocaine and increased immobility in the forced swim test associated with elevated cAMP response element-binding protein expression in nucleus accumbens". The Journal of Neuroscience. 21 (18): 7397–7403. doi:10.1523/JNEUROSCI.21-18-07397.2001. ISSN   1529-2401. PMC   4205577 . PMID   11549750.
  38. Bućan, Maja; Abel, Ted (2002). "The mouse: genetics meets behaviour". Nature Reviews Genetics. 3 (2): 114–123. doi:10.1038/nrg728. ISSN   1471-0056. PMID   11836505. S2CID   5985686.
  39. Yan, Hua-Cheng; Cao, Xiong; Das, Manas; Zhu, Xin-Hong; Gao, Tian-Ming (August 2010). "Behavioral animal models of depression". Neuroscience Bulletin. 26 (4): 327–337. doi:10.1007/s12264-010-0323-7. ISSN   1673-7067. PMC   5552573 . PMID   20651815.
  40. Hao, Y., Ge, H., Sun, M., & Gao, Y. (2019). Selecting an Appropriate Animal Model of Depression. International journal of molecular sciences, 20(19), 4827. https://doi.org/10.3390/ijms20194827